GnRH agonists: risk of major CV events incurring increased costs

  • PDF / 167,328 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 28 Downloads / 172 Views

DOWNLOAD

REPORT

1173-5503/20/0868-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 12 Dec 2020 No. 868

1

Data Loading...

Recommend Documents
GnRH agonists: risk of major CV events incurring increased costs

132 30 148KB

Evidence of CV events with calcium/vitamin D not convincing

177 53 138KB

ADHD drugs not associated with serious CV events in children

177 114 166KB

The risk of major cardiovascular events for adults with transfemoral amputation

104 67 605KB

Do Inhaled Anticholinergics Increase or Decrease the Risk of Major Cardiovascular Events?

142 21 140KB

Increased risk of infections with alemtuzumab?

174 90 120KB

CV

180 24 6KB

Risk of serious neuropsychiatric events with montelukast

183 83 165KB

Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-

136 36 728KB

LHRH Agonists

182 55 4MB

Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a

138 41 1MB

Risk of Major Adverse Cardiovascular Events Associated with Concomitant Use of Antidepressants and Non-steroidal Anti-in

129 49 2MB